Structured support may limit weight regain after stopping GLP-1 drugs
A pilot randomized trial suggests that structured support after stopping GLP-1 medication can help attenuate early weight regain.
FTMQ Health, written by our newsroom6 views
Medical Xpress reported that structured support may help limit early weight regain in individuals who stop taking glucagon-like peptide-1 (GLP-1) receptor agonists. The findings come from a pilot randomized trial published in the journal Obesity Science & Practice. [1]
GLP-1 receptor agonists are effective treatments for obesity. However, patients frequently discontinue the medications due to cost, insurance coverage limitations, side effects, and personal preferences, which often leads to rapid weight regain, Medical Xpress reported. [1]
Tirzepatide is a GLP-1 receptor agonist and GIP analog administered through subcutaneous injections. It is used as an antidiabetic medication for type 2 diabetes and for weight loss under brand names including Mounjaro and Zepbound. [3]
The trial results indicate that offering structured support following medication discontinuation may help attenuate early weight regain for patients. [1]
In short
- GLP-1 receptor agonists are effective obesity treatments, but stopping them frequently leads to rapid weight regain.
- Patients often discontinue GLP-1 treatments due to cost, side effects, or insurance coverage limitations.
- A pilot randomized trial published in Obesity Science & Practice showed structured support may attenuate early weight regain.
Sources
Every paragraph above points to the numbered items it rests on. Read the originals here.
- [1]Pilot trial suggests structured support may help limit weight regain after GLP-1 treatmentMedical Xpress, 2h ago (the report this story comes from)
Background
- [2]School dog on Wikipedia
- [3]Tirzepatide on Wikipedia
Our newsroom writes these reports with the help of software, from the 3 sources listed and nothing else, and checks them against those sources. Facts can still be wrong or move on; the originals are the record. Spotted a mistake? Write to daniel@monsterkong.com.
Related from FTMQ Health
Earlier reports of ours on the same people and subjects.
- WHO guidelines advise against obesity drugs for children under tenTop Stories, 1h ago
More in Top Stories
- Caribou Biosciences Shuts Down After Failing to Secure Trial Funding1h ago
- WHO guidelines advise against obesity drugs for children under ten1h ago
- WHO assesses low plague epidemic risk following Russian lab death9h ago
- Over one million never smokers in the UK now use e-cigarettes23h ago
- Cancer trial drug may target tumors differently than originally believed1d ago
- Somerset perinatal mental health charity faces closure of waiting list1d ago
Get the day in one email
Reports like this one, the top news of the last 24 hours, every morning. Free, one email a day; readers can comment under every report.
By signing up you agree to our terms and privacy policy. Unsubscribe any time.
Comments
Loading
Join the conversation
Comments are open to readers of our daily email: the top news of the last 24 hours, every morning, free. Sign up and the comment box opens.
Already on the list? Enter the same address and we will send a sign-in link.
By signing up you agree to our terms and privacy policy. Unsubscribe any time.